November
Venture Capital & Private Equity
Investment Challenges and Opportunities in Emerging Biotech Markets
Bruce Kovacs
Afecta Pharmaceuticals
David Crean
Managing Partner & Partner Cardiff Advisory LLC & 1004 Venture Partners
George Ng
Board Director, President & COO Calidi Biotherapeutics
Igor O. Nasonkin
CEO Phythera Therapeutics
John Mattison
Operating Partner, CMIO Arsenal Capital Partners
Klaus Simonsen
Vice President, Head of External Research & Innovation Lundbeck
Mehran Moghaddam
CEO OROX Biosciences, Inc.Our Agenda
Private Equity, Venture Capital & Strategic Partnerships
Topic TBC
Igor O. Nasonkin,
CEO,
Phythera Therapeutics
Private Equity, Venture Capital & Strategic Partnerships
Collaborative Chemistry: The Business of Partnerships in Drug Innovation (Topic TBC)
Klaus Simonsen,
Vice President, Head of External Research & Innovation,
Lundbeck
Private Equity, Venture Capital & Strategic Partnerships
Crossroads Between Life Sciences and Cryptocurrency in Investing
George Ng,
Chief Executive Officer,
Processa Pharmaceuticals
Private Equity, Venture Capital & Strategic Partnerships
Strategic Alliances and Investment Strategies: Fueling the Future of Drug Discovery
Private Equity, Venture Capital & Strategic Partnerships
The Role of Venture Partnerships in Drug Discovery (Topic TBC)
Bruce Kovacs,
President/CEO,
Afecta Pharmaceuticals
Private Equity, Venture Capital & Strategic Partnerships
Aligning Capital, Capability, and Curiosity: The Future of Venture and Partnership in Drug Discovery
Private Equity & Venture Capital
Navigating Financial Risks and Rewards in Biotech: Investment Trends in 2025 and Strategies for 2026
David Crean,
Managing Partner & Partner,
Cardiff Advisory LLC & 1004 Venture Partners
Private Equity & Venture Capital
Balancing Cost-Effectiveness with Data Reliability in Decentralized Models
Private Equity & Venture Capital
Crossroads Between Life Sciences and Cryptocurrency in Investing
George Ng,
Chief Executive Officer,
Processa Pharmaceutical
Private Equity & Venture Capital
The Next Wave in Life Science Investing (Topic TBC)
John Mattison,
Operating Partner, CMIO,
Arsenal Capital Partners
Private Equity & Venture Capital
De-Risking Investment in Clinical Trials: Strategies for Startups and VCs
Anthony Maida,
Chief Clinical Officer – Translational Medicine,
Oncotelic Therapeutics, Inc.
Engage in Real Conversations That Matter
Our unique roundtable format fosters meaningful dialogue—not lectures—so you gain actionable insights from every discussion. Choose up to four roundtable sessions, each limited to 20 participants, and connect with senior-level peers in a relaxed, collaborative setting.
Further Information
Interested in attending this virtual roundtable or running your own? Drop us a message today and we will get in touch
Here To Help
Need help registering your team? Just get in touch and a member of the team will be happy to help.
Hard Rock Hotel San Diego
Payment Securely powered by stripe